Page 41 - PowerPoint Presentation
P. 41
Metastatic melanoma
Multidisciplinary team management
Immunotherapy
Interferon α-2b
Interleukin-2
Ipilimumab
Targets cytotoxic T lymphocyte
antigen 4 (CTLA-4)
Vemurafenib
BRAF inhibitor
Nivolumab/Pembrolizumab
Monoclonal antibodies targeting
programmed death 1 (PD1)
protein
Target therapy
MEK, Kit inhibitor
Chemotherapy
Radiotherapy
Oligo-metastastic disease
Surgical resection for palliation of
pain/ulcers